CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting
Abstract Bispecific antibodies (BsAbs) represent an innovative class of off-the-shelf T-cell redirecting agents and are considered among the most promising immunotherapeutic strategies for the treatment of lymphoma. Notably, anti-CD20 × CD3 BsAbs have exhibited substantial monotherapy efficacy in pa...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2025-04-01
|
| シリーズ: | Journal of Hematology & Oncology |
| オンライン･アクセス: | https://doi.org/10.1186/s13045-025-01695-1 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|